NCT06668831 (FibCA-HD) is a clinical trial in Hemodialysis, sponsored by Antonio Bellasi.

Who is sponsoring NCT06668831?

NCT06668831 is sponsored by Antonio Bellasi.

What condition does NCT06668831 study?

NCT06668831 studies Hemodialysis.

Is NCT06668831 still recruiting?

NCT06668831 is currently recruiting now. Last updated 5 August 2025.

Last reviewed 2025-08-05 · How we verify

NCT06668831: FibCA-HD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fibroblast Growth Factor 23 and Risk of Cardiac Arrhythmias in Hemodialysis Patients

Recruiting now Last updated 5 August 2025

What this trial tests

trial in Hemodialysis in 30 participants. Currently enrolling.

Timeline

12 October 2024

Primary endpoint
31 October 2025

30 December 2025

Quick facts

Lead sponsor	Antonio Bellasi
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	30
Start date	12 October 2024
Primary completion	31 October 2025
Estimated completion	30 December 2025
Sites	1 location across Switzerland

Conditions studied

Hemodialysis — all drugs for Hemodialysis →

Sponsor

Antonio Bellasi

Who can join

18 and older, any sex, with Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Despite recent progress in the field of hemodialysis (HD), mortality remains unacceptably high, particularly due to cardiac arrhythmias. Recent evidence suggests that fibroblast growth factor 23 (FGF23) is implicated in the pathogenesis of cardiac arrhythmias and sudden death. However, several aspects of both the pathogenetic mechanism(s) as well as the actual association in individuals with Chronic Kidney Disease (CKD) and the effect of dialysis clearance of FGF23 need to be elucidated. The investigators aim at testing the independent association of FGF23 changes due to dialysis removal and electrocardiographic (ECG) abnormalities (namely QTc prolongation) in a well characterized sample of patients undergoing maintenance HD. The study will be developed in the Division of Nephrology, Ente Ospedaliero Cantonale.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hemodialysis

Currently open trials in the same condition.

NCT07278973 — Hemodiafiltration Versus Hemodialysis in Older People · NA · recruiting
NCT07438925 — Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation · active not recruiting
NCT07234890 — Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury. · Phase 2 · recruiting
NCT07512895 — The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treat · NA · recruiting
NCT07076888 — Aerobic Exercises and Hemodialysis Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06668831 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Antonio Bellasi
Last refreshed: 5 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06668831.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing